Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

435 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical value.
Battaglin F, Baca Y, Millstein J, Yang Y, Xiu J, Arai H, Wang J, Ou FS, Innocenti F, Mumenthaler SM, Jayachandran P, Kawanishi N, Lenz A, Soni S, Algaze S, Zhang W, Khoukaz T, Roussos Torres E, Seeber A, Abraham JP, Lou E, Philip PA, Weinberg BA, Shields AF, Goldberg RM, Marshall JL, Venook AP, Korn WM, Lenz HJ. Battaglin F, et al. Among authors: innocenti f. J Immunother Cancer. 2024 Jan 11;12(1):e007939. doi: 10.1136/jitc-2023-007939. J Immunother Cancer. 2024. PMID: 38212126 Free PMC article.
Common variation in a long non-coding RNA gene modulates variation of circulating TGF-β2 levels in metastatic colorectal cancer patients (Alliance).
Quintanilha JCF, Sibley AB, Liu Y, Niedzwiecki D, Halabi S, Rogers L, O'Neil B, Kindler H, Kelly W, Venook A, McLeod HL, Ratain MJ, Nixon AB, Innocenti F, Owzar K. Quintanilha JCF, et al. Among authors: innocenti f. medRxiv [Preprint]. 2023 Dec 4:2023.12.04.23298815. doi: 10.1101/2023.12.04.23298815. medRxiv. 2023. Update in: BMC Genomics. 2024 May 14;25(1):473. doi: 10.1186/s12864-024-10354-7 PMID: 38106038 Free PMC article. Updated. Preprint.
Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer.
Arai H, Yang Y, Baca Y, Millstein J, Denda T, Ou FS, Innocenti F, Takeda H, Kubota Y, Doi A, Horie Y, Umemoto K, Izawa N, Wang J, Battaglin F, Jayachandran P, Algaze S, Soni S, Zhang W, Goldberg RM, Hall MJ, Scott AJ, Hwang JJ, Lou E, Weinberg BA, Marshall J, Goel S, Xiu J, Michael Korn W, Venook AP, Sunakawa Y, Lenz HJ. Arai H, et al. Among authors: innocenti f. Eur J Cancer. 2024 Apr;201:113914. doi: 10.1016/j.ejca.2024.113914. Epub 2024 Feb 10. Eur J Cancer. 2024. PMID: 38359495
Evaluating the utility of ZNF331 promoter methylation as a prognostic and predictive marker in stage III colon cancer: results from CALGB 89803 (Alliance).
Nakasone ES, Zemla TJ, Yu M, Lin SY, Ou FS, Carter K, Innocenti F, Saltz L, Grady WM, Cohen SA. Nakasone ES, et al. Among authors: innocenti f. Epigenetics. 2024 Dec;19(1):2349980. doi: 10.1080/15592294.2024.2349980. Epub 2024 May 8. Epigenetics. 2024. PMID: 38716804 Free PMC article. Clinical Trial.
Common variation in a long non-coding RNA gene modulates variation of circulating TGF-β2 levels in metastatic colorectal cancer patients (Alliance).
Quintanilha JCF, Sibley AB, Liu Y, Niedzwiecki D, Halabi S, Rogers L, O'Neil B, Kindler H, Kelly W, Venook A, McLeod HL, Ratain MJ, Nixon AB, Innocenti F, Owzar K. Quintanilha JCF, et al. Among authors: innocenti f. BMC Genomics. 2024 May 14;25(1):473. doi: 10.1186/s12864-024-10354-7. BMC Genomics. 2024. PMID: 38745123 Free PMC article.
Gene signatures derived from transcriptomic-causal networks stratify colorectal cancer patients for effective targeted therapy.
Yazdani A, Lenz HJ, Pillonetto G, Mendez-Giraldez R, Yazdani A, Sanoff H, Hadi R, Samiei E, Venook AP, Ratain MJ, Rashid N, Vincent BG, Qu X, Wen Y, Kosorok M, Symmans WF, Shen JPYC, Lee MS, Kopetz S, Nixon AB, Bertagnolli MM, Perou CM, Innocenti F. Yazdani A, et al. Among authors: innocenti f. Commun Med (Lond). 2025 Jan 8;5(1):9. doi: 10.1038/s43856-024-00728-z. Commun Med (Lond). 2025. PMID: 39779996 Free PMC article.
A phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancer.
Sanoff HK, Deal AM, Patel J, Sorah JD, Gaddy J, O'Neil B, Turk A, Irvin W, Boles J, Lee MS, McRee A, Wardell AC, Weck KE, Basch E, Wood WA, Innocenti F. Sanoff HK, et al. Among authors: innocenti f. Oncologist. 2024 Sep 6;29(9):786-793. doi: 10.1093/oncolo/oyae122. Oncologist. 2024. PMID: 38837045 Free PMC article. Clinical Trial.
435 results